Clinical bottom line
The management of pancreatic cystic lesions increasingly favors selective surgical resection guided by risk stratification, with active surveillance as a safe alternative for many asymptomatic, low-risk cysts. Advances in imaging and cyst fluid analysis have improved differentiation between benign and premalignant or malignant cysts, allowing tailored approaches that balance surgical morbidity against malignancy risk. Current evidence supports surveillance protocols for stable cysts without high-risk features, reserving resection for cysts with suspicious imaging or clinical changes (Gerry et al., 2017; Lim et al., 2027).
What the evidence shows
Pancreatic cystic lesions encompass a spectrum from benign pseudocysts to mucinous cystic neoplasms with malignant potential. Gerry et al. (2017) describe a paradigm shift toward selective resection based on cyst characteristics such as size, mural nodules, main pancreatic duct involvement, and cytology.
Lim et al. (2027) review surgical approaches, highlighting that drainage procedures are generally reserved for pseudocysts, whereas true cystic neoplasms warrant resection if high-risk features are present. Their analysis underscores the importance of multidisciplinary evaluation incorporating cross-sectional imaging, endoscopic ultrasound, and cyst fluid biomarkers.
Liao et al. (2007) emphasize that many asymptomatic pancreatic cysts remain stable over time, with low rates of progression to malignancy, supporting active surveillance with periodic imaging.
Salimgereeva et al. (2026), while focusing on neuroendocrine tumors, provide comparative survival data favoring surveillance in selected low-risk lesions, reinforcing the principle of individualized management.
Surgical resection carries significant morbidity and potential impact on pancreatic function, necessitating careful patient selection (Surgical Management of Hepatobiliary and Pancreatic Disorders, 2010).
Caveats and uncertainty
Heterogeneity in cyst types and diagnostic criteria complicates management algorithms.
Long-term natural history data for many cyst subtypes remain limited.
Optimal surveillance intervals and imaging modalities are not standardized.
Risk stratification tools require further validation in diverse populations.
Surgical decision-making must consider patient comorbidities and preferences.
How this may change practice
Clinicians should adopt risk-based algorithms integrating imaging and cyst fluid analysis to guide management.
Active surveillance protocols can reduce unnecessary surgeries and associated morbidity.
Multidisciplinary teams including surgeons, gastroenterologists, radiologists, and pathologists are essential for optimal care.
Patient education on risks, benefits, and uncertainties of surveillance versus surgery is critical.
Future research should focus on refining biomarkers and imaging techniques to enhance diagnostic accuracy.